Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report), with a ...

Allogene Therapeutics (ALLO) announced the publication of data from its Phase 1 ALPHA and ALPHA2 clinical studies of cemacabtagene ...

Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on ...

SOUTH SAN FRANCISCO - Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology firm specializing in allogeneic CAR T therapies currently valued at approximately $299 million, has published new data ...

Allogene Therapeutics Inc (NASDAQ:ALLO). shares have tumbled to a 52-week low, with the stock price touching down at $1.33. According to InvestingPro data, the stock appears undervalued, with analyst ...

Gabe Gelman, head of Americas equity capital markets at Goldman Sachs Group Inc., is leaving the firm after more than 25 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In 2018, the former leadership of team from Kite Pharma founded Allogene, on a mission to outdo the CAR-T cancer cell therapies they had just sold to Gilead for $12 billion with an "off-the-shelf ...

T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...